H-series protein kinase inhibitors and potential clinical applications.

During the course of generating derivatives of N-(6-aminohexyl)-5-chloro-1-naphthalene-sulfonamide, a synthetic calmodulin inhibitor, we came across several analogues with shorter alkyl chains that exhibited inhibition of serine/threonine protein kinase activities in an ATP-competitive manner. Certain derivatives proved to be selective inhibitors of protein kinases useful for elucidation of relevant functions of the enzymes. One of them turned out to be a unique vasodilator that preferentially suppresses delayed cerebral vasospasm, a critical complication of subarachnoid hemorrhage, without significant changes in systemic blood pressure. The compound in question, 1-(5-isoquinolinesulfonyl)-homopiperazine, was identified from sequential development of protein kinase inhibitors with isoquinolinesulfonyl structures, which occupy the adenine pocket of the ATP-binding site of the enzyme. It recently has been proposed that the target kinase responsible for vasodilation by 1-(5-isoquinolinesulfonyl)-homopiperazine may be Rho-kinase, which regulates phosphorylation of myosin light chains and vasocontraction. Because protein phosphorylation plays important roles in regulation of various cellular functions, the foregoing is a good example of current progress in the development of protein kinase inhibitors with potential clinical applications.

[1]  S. Kawamoto,et al.  Naphthalenesulfonamides as calmodulin antagonists and protein kinase inhibitors. , 1986, Molecular pharmacology.

[2]  H. Hidaka,et al.  KN‐62: A Specific Ca2+/calmodulin‐dependent Protein Kinase Inhibitor as a Putative Function‐searching Probe for Intracellular Signal Transduction , 1996 .

[3]  T. Sasaki,et al.  Involvement of rho p21 in the GTP-enhanced calcium ion sensitivity of smooth muscle contraction. , 1992, The Journal of biological chemistry.

[4]  H. Hidaka,et al.  Unique inhibitory action of the synthetic compound 2-[N-(2-aminoethyl)-N-(5-isoquinolinesulfonyl)] amino-N-(4-chlorocinnamyl)-N-methylbenzylamine (CKA-1306) against calcium/calmodulin-dependent protein kinase I. , 1998, Biochemical pharmacology.

[5]  Yoshiharu Matsuura,et al.  Phosphorylation and Activation of Myosin by Rho-associated Kinase (Rho-kinase)* , 1996, The Journal of Biological Chemistry.

[6]  H. Hidaka,et al.  Effects of HA1077, a protein kinase inhibitor, on myosin phosphorylation and tension in smooth muscle. , 1991, European journal of pharmacology.

[7]  K. Takakura,et al.  Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial. , 1992, Journal of neurosurgery.

[8]  R. Huber,et al.  Phosphotransferase and substrate binding mechanism of the cAMP‐dependent protein kinase catalytic subunit from porcine heart as deduced from the 2.0 A structure of the complex with Mn2+ adenylyl imidodiphosphate and inhibitor peptide PKI(5‐24). , 1993, The EMBO journal.

[9]  Hao Ren,et al.  Regulation of the Calmodulin-stimulated Protein Phosphatase, Calcineurin* , 1998, The Journal of Biological Chemistry.

[10]  Yanqing Zhu,et al.  Transforming Growth Factor-β1 Stimulates Protein Kinase A in Mesangial Cells* , 1998, The Journal of Biological Chemistry.

[11]  H. Kawasaki,et al.  Tissue-specific expression of three distinct types of rabbit protein kinase C , 1987, Nature.

[12]  H. Karaki,et al.  Contractile and relaxant effects of phorbol ester in the intestinal smooth muscle of guinea‐pig taenia caeci , 1993, British journal of pharmacology.

[13]  H. Hidaka,et al.  Vasodilator actions of HA1077 in vitro and in vivo putatively mediated by the inhibition of protein kinase , 1989, British journal of pharmacology.

[14]  K. Shindo,et al.  Selective inhibition of myosin phosphorylation and tension of hyperplastic arteries by the kinase inhibitor HA1077. , 1995, European journal of pharmacology.

[15]  A. Ridley,et al.  Signal transduction pathways regulating Rho‐mediated stress fibre formation: requirement for a tyrosine kinase. , 1994, The EMBO journal.

[16]  K. Sako,et al.  HA1077, a novel calcium antagonistic antivasospasm drug, increases both cerebral blood flow and glucose metabolism in conscious rats. , 1991, European journal of pharmacology.

[17]  T. Hunter,et al.  The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. , 1988, Science.

[18]  H. Hidaka,et al.  Naphthalenesulfonamides as calmodulin antagonists. , 1983, Methods in enzymology.

[19]  Y. Sasaki Inhibition of myosin light chain phosphorylation in cultured smooth muscle cells by HA1077, a new type of vasodilator. , 1990, Biochemical and biophysical research communications.

[20]  M. Mayberg,et al.  Local application of calcium antagonists inhibits intimal hyperplasia after arterial injury. , 1994, Neurosurgery.

[21]  M. Hagiwara,et al.  A newly synthesized selective casein kinase I inhibitor, N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide, and affinity purification of casein kinase I from bovine testis. , 1989, The Journal of biological chemistry.

[22]  A. Nairn,et al.  Calcium/calmodulin-dependent protein kinases. , 1994, Seminars in cancer biology.

[23]  R. Huber,et al.  Crystal Structures of Catalytic Subunit of cAMP-dependent Protein Kinase in Complex with Isoquinolinesulfonyl Protein Kinase Inhibitors H7, H8, and H89 , 1996, The Journal of Biological Chemistry.

[24]  M Hori,et al.  Calcium movements, distribution, and functions in smooth muscle. , 1997, Pharmacological reviews.

[25]  H. Hidaka,et al.  Calmodulin antagonists' binding sites on calmodulin. , 1983, Pharmacology.

[26]  M. Hagiwara,et al.  ML-9 inhibits the vascular contraction via the inhibition of myosin light chain phosphorylation. , 1988, Molecular pharmacology.

[27]  H. Hidaka,et al.  The effects of HA compound calcium antagonists on delayed cerebral vasospasm in dogs. , 1986, Journal of neurosurgery.

[28]  D. Hartshorne,et al.  Modulator protein as a component of the myosin light chain kinase from chicken gizzard. , 1978, Biochemistry.

[29]  H. Hidaka,et al.  N-(2-Aminoethyl)-5-isoquinolinesulfonamide, a newly synthesized protein kinase inhibitor, functions as a ligand in affinity chromatography. Purification of Ca2+-activated, phospholipid-dependent and other protein kinases. , 1985, The Journal of biological chemistry.

[30]  Shibuya Masato,et al.  Possible prophylactic potential of HA1077, a Ca2+ channel antagonist and vasodilator, on chronic cerebral vasospasm. , 1992 .

[31]  H. Hidaka,et al.  Pharmacology of protein kinase inhibitors. , 1992, Annual review of pharmacology and toxicology.

[32]  H. Tokumitsu,et al.  KN-62, 1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazi ne, a specific inhibitor of Ca2+/calmodulin-dependent protein kinase II. , 1990, The Journal of biological chemistry.

[33]  S. Kawamoto,et al.  Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. , 1984, Biochemistry.

[34]  Robert J. Lefkowitz,et al.  Switching of the coupling of the β2-adrenergic receptor to different G proteins by protein kinase A , 1997, Nature.

[35]  K. Walsh The Protein Kinase Family , 1987 .

[36]  S H Kim,et al.  Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. , 1998, Science.

[37]  M. Donowitz,et al.  Subcellular Redistribution Is Involved in Acute Regulation of the Brush Border Na+/H+ Exchanger Isoform 3 in Human Colon Adenocarcinoma Cell Line Caco-2 , 1998, The Journal of Biological Chemistry.

[38]  J. Peterson,et al.  Intracellular calcium, myosin light chain phosphorylation, and contractile force in experimental cerebral vasospasm. , 1996, Neurosurgery.

[39]  H. Hidaka,et al.  Mechanism of action of a novel antivasospasm drug, HA1077. , 1987, The Journal of pharmacology and experimental therapeutics.

[40]  K. Sugita,et al.  Endothelin: a potential modulator of cerebral vasospasm. , 1990, European journal of pharmacology.

[41]  H. Hidaka,et al.  Vasodilatory action of HA1004 [N-(2-guanidinoethyl)-5-isoquinolinesulfonamide], a novel calcium antagonist with no effect on cardiac function. , 1984, The Journal of pharmacology and experimental therapeutics.

[42]  M. Hagiwara,et al.  Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. , 1990, The Journal of biological chemistry.

[43]  J. Miyazaki,et al.  Myosin light-chain phosphorylation controls insulin secretion at a proximal step in the secretory cascade. , 1997, American journal of physiology. Endocrinology and metabolism.

[44]  H. Hidaka,et al.  Selective inhibition of catalytic activity of smooth muscle myosin light chain kinase. , 1987, The Journal of biological chemistry.

[45]  H. Hidaka,et al.  Ca2+ -calmodulin-dependent phosphorylation and platelet secretion , 1980, Nature.

[46]  Shuh Narumiya,et al.  Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension , 1997, Nature.

[47]  J. Ando,et al.  An essential role of myosin light‐chain kinase in the regulation of agonist‐ and fluid flow‐stimulated Ca2+ influx in endothelial cells , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[48]  T. Yamamoto,et al.  Rho‐associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. , 1996, The EMBO journal.

[49]  A. Levitzki,et al.  Tyrosine kinase inhibition: an approach to drug development. , 1995, Science.

[50]  T. Decker,et al.  Stat1 combines signals derived from IFN‐γ and LPS receptors during macrophage activation , 1998, The EMBO journal.

[51]  H. Hidaka,et al.  A novel vascular relaxing agent, N-(6--aminohexyl)-5-chloro-1-naphthalensulfonamide which affects vascular smooth muscle actomyosin. , 1978, The Journal of pharmacology and experimental therapeutics.

[52]  K. Uemura,et al.  Direct evidence for a key role of protein kinase C in the development of vasospasm after subarachnoid hemorrhage. , 1992, Journal of neurosurgery.

[53]  H. Hidaka,et al.  Disorganization by calcium antagonists of actin microfilament in aortic smooth muscle cells. , 1987, The American journal of physiology.

[54]  H. Hidaka,et al.  Molecular and cellular pharmacology of a calcium/calmodulin-dependent protein kinase II (CaM kinase II) inhibitor, KN-62, and proposal of CaM kinase phosphorylation cascades. , 1996, Advances in pharmacology.

[55]  K. Sugita,et al.  Blockade of intracellular actions of calcium may protect against ischaemic damage to the gerbil brain , 1991, British journal of pharmacology.

[56]  Kozo Kaibuchi,et al.  Regulation of Myosin Phosphatase by Rho and Rho-Associated Kinase (Rho-Kinase) , 1996, Science.

[57]  Peter Lipp,et al.  Calcium - a life and death signal , 1998, Nature.

[58]  M. Hagiwara,et al.  Specific binding of a novel compound, N-[2-(methylamino)ethyl]-5-isoquinolinesulfonamide (H-8) to the active site of cAMP-dependent protein kinase. , 1987, Molecular pharmacology.

[59]  Kenneth Maiese,et al.  Nitric oxide: a downstream mediator of calcium toxicity in the ischemic cascade , 1994, Neuroscience Letters.

[60]  T. Soderling,et al.  Characterization of Ca2+/calmodulin-dependent protein kinase IV. Role in transcriptional regulation. , 1994, The Journal of biological chemistry.